GVHD can range from mild and temporary to life-threatening and chronic — but the deadly, debilitating cases are rare now. As ...

Fred Hutch bioengineer Dr. Matthias Stephan is working to develop a special foam that could help make gene therapy for blood ...

In this episode of the Oncology Insights Podcast, Dr. Petros Grivas welcomes Dr. Christina Rodriguez to discuss her journey ...

A new $5.2 million grant from the Washington Research Foundation will help develop a new clinical trials program between Fred ...

On Oct. 9, 2025, Fred Hutch Cancer Center employees with decades of service were honored at a luncheon celebrating their ...

As chief medical officer, Tom Purcell, MD, MBA, is overseeing an organization-wide initiative to improve the delivery of care ...

Viral immunologist Paul Thomas, PhD, is working to turn the “incredible potential” of the immune system into real-life diagnostic and therapeutic applications that will improve vaccination strategies ...

Stuart and Molly Sloan add to their 2022 transformational gift to boost their impact on research and care SEATTLE – July 22, 2025 – A Fred Hutch Cancer Center outpatient complex serving more than ...

Philanthropy fuels Fred Hutch’s breakthroughs. Our community's support drives life-changing discoveries, strengthens patient and caregiver experiences, and helps build the next generation of ...

It’s official — the Fred Hutch/University of Washington Cancer Consortium is now serving the entire Evergreen state. For years, the Cancer Consortium — composed of Fred Hutch, the University of ...

Today, Fred Hutch announced that in 2025 the Obliteride community raised $9.2 million for groundbreaking research. This amount brings Obliteride’s cumulative fundraising total to more than $67 million ...